[HTML][HTML] Breast cancer heterogeneity and response to novel therapeutics
M Baliu-Piqué, A Pandiella, A Ocana - Cancers, 2020 - mdpi.com
Simple Summary Breast cancer is a heterogeneous disease that is driven by genetic,
epigenetic and phenotypic modifications and is also affected by the microenvironment and …
epigenetic and phenotypic modifications and is also affected by the microenvironment and …
[PDF][PDF] Breast Cancer Heterogeneity and Response to Novel Therapeutics
M Baliu-Piqué, A Pandiella, A Ocana - pdfs.semanticscholar.org
Targeted cancer therapies against oncogenic drivers are actively being developed and
tested in clinical trials. Targeting an oncogenic driver may only prove effective if the mutation …
tested in clinical trials. Targeting an oncogenic driver may only prove effective if the mutation …
Breast Cancer Heterogeneity and Response to Novel Therapeutics.
M Baliu-Piqué, A Pandiella, A Ocana - Cancers, 2020 - search.ebscohost.com
Abstract Simple Summary: Breast cancer is a heterogeneous disease that is driven by
genetic, epigenetic and phenotypic modifications and is also affected by the …
genetic, epigenetic and phenotypic modifications and is also affected by the …
Breast Cancer Heterogeneity and Response to Novel Therapeutics.
M Baliu-Piqué, A Pandiella, A Ocana - Cancers, 2020 - europepmc.org
Targeted cancer therapies against oncogenic drivers are actively being developed and
tested in clinical trials. Targeting an oncogenic driver may only prove effective if the mutation …
tested in clinical trials. Targeting an oncogenic driver may only prove effective if the mutation …
[PDF][PDF] Breast Cancer Heterogeneity and Response to Novel Therapeutics
M Baliu-Piqué, A Pandiella, A Ocana - researchgate.net
Targeted cancer therapies against oncogenic drivers are actively being developed and
tested in clinical trials. Targeting an oncogenic driver may only prove effective if the mutation …
tested in clinical trials. Targeting an oncogenic driver may only prove effective if the mutation …
[HTML][HTML] Breast Cancer Heterogeneity and Response to Novel Therapeutics
M Baliu-Piqué, A Pandiella, A Ocana - Cancers, 2020 - ncbi.nlm.nih.gov
Targeted cancer therapies against oncogenic drivers are actively being developed and
tested in clinical trials. Targeting an oncogenic driver may only prove effective if the mutation …
tested in clinical trials. Targeting an oncogenic driver may only prove effective if the mutation …
Breast Cancer Heterogeneity and Response to Novel Therapeutics.
M Baliu-Pique, A Pandiella, A Ocana - Cancers, 2020 - go.gale.com
Breast cancer is a heterogeneous disease that is driven by genetic, epigenetic and
phenotypic modifications and is also affected by the microenvironment and the metabolism …
phenotypic modifications and is also affected by the microenvironment and the metabolism …
Breast Cancer Heterogeneity and Response to Novel Therapeutics
M Baliu-Piqué, A Pandiella, A Ocana - Cancers, 2020 - pubmed.ncbi.nlm.nih.gov
Targeted cancer therapies against oncogenic drivers are actively being developed and
tested in clinical trials. Targeting an oncogenic driver may only prove effective if the mutation …
tested in clinical trials. Targeting an oncogenic driver may only prove effective if the mutation …
Breast Cancer Heterogeneity and Response to Novel Therapeutics
M Baliu-Piqué, A Pandiella, A Ocaña - 2020 - digital.csic.es
Targeted cancer therapies against oncogenic drivers are actively being developed and
tested in clinical trials. Targeting an oncogenic driver may only prove effective if the mutation …
tested in clinical trials. Targeting an oncogenic driver may only prove effective if the mutation …